Certain steps of antibody drug discovery require advanced expertise, and companies offering these specialized services have attracted significant attention of drug / therapy developers. Two such specific services are to reduce antibody immunogenicity (humanization) and enhance its affinity (affinity maturation). The ‘Antibody Humanization and Affinity Maturation: Services and Platforms, 2017-2030’ report provides a comprehensive view on the current landscape and the future outlook of this market. Some of the most interesting insights from our study are presented below.
A Healthy Mix of Services / Platform Providers …
Close to 60 companies currently offer services / platforms for antibody humanization and / or affinity maturation
… Offering Deep Expertise in Antibody Discovery
These companies are rapidly evolving to offer complete antibody discovery and optimization services to antibody drug developers
Multiple Business Models, Catering to Variety of Client Needs
The increasing geographical reach, combined with flexible deal structures and business models, has attracted significant business
Innovative Approaches Gradually Unfolding
To remain competitive in this domain, the companies have adopted novel methods / techniques catering to the evolving demands of the drug developers
Benchmark Analysis Offers Credible Insights
Benchmark analysis, comparing key parameters, highlights that many companies in North America (Peer Group III) provide both the services
Steady Growth Expected in the Long-term …
Driven by the need for safer antibody therapeutics and the rising demand for contract services, the market is likely to witness continuous growth in the coming decade
… Driven by Developments in Emerging Markets
Majority of the market share is distributed between North America and EU; China and some other emerging markets are likely to grow at a faster rate
To know more please click here. For any queries / suggestions or if you’d like to get access to the full research results, please do not hesitate to contact us at email@example.com.